AstraZeneca’s ZS-9 setback last month did Relypsa a favor: It handed Veltassa sole control of the hyperkalemia market. That didn't hurt Relypsa’s chances to sell itself--and now, Galenica has shelled out $1.53B for Relypsa to build up its Vifor business ahead of a planned spinout.
AstraZeneca’s ZS-9 rejection last week leaves Relypsa and its new med Veltassa in sole control of the next-gen hyperkalemia market, worth up to $6 billion. Good thing, too: Execs say Veltassa's launch will be slow going.
Redwood City, CA-based Relypsa has hired an investment bank to check out M&A offers, Reuters reported. Relypsa isn't commenting but the news service says several companies that had previously bid on ZS Pharma, including Actelion, are eyeing Relypsa.